Valore202020212022202320242025TTMSpese di vendita, generali e amministrative15.57 M18.21 M22.51 M17.3 M18.17 M18.46 M18.46 MRicerca e sviluppo12.32 M33.91 M13.99 M15.71 M12.47 M17.73 M17.73 MReddito operativo-26.45 M-49.21 M-22.52 M-24.73 M-21.48 M-36.62 M-36.62 MProventi non operativi, Totale4.52 M5.94 M-3.29 M1.45 M2.9 M-32.03 M-32.03 MOneri finanziari, al netto degli interessi capitalizzati———22 K———Proventi non operativi, esclusi gli oneri finanziari1.64 M4.46 M-1.14 M1.43 M3.57 M-31.9 M-31.9 MEntrate/uscite straordinarie2.88 M1.49 M-2.15 M-4 000-670 K-132 K-132 KUtile al lordo delle imposte-21.92 M-43.27 M-25.81 M-23.28 M-18.58 M-68.65 M-68.65 MQuota di utile———————Imposte-1.24 M0541 K-1.8 M0-5.28 M-7.13 MInteressi di minoranza-36 K-251 K-80 K7 00027 K166 K166 KAltri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate-20.65 M-43.02 M-26.27 M-21.49 M-18.61 M-63.53 M-63.53 MAttività cessate———————Utile netto-20.65 M-43.02 M-26.27 M-21.49 M-18.61 M-63.53 M-63.53 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-20.65 M-43.02 M-26.27 M-21.49 M-18.61 M-63.53 M-63.53 MUtile base per azione (EPS base)——-0.15-0.12-0.09-0.28-0.28Utile diluito per azione (EPS diluito)——-0.15-0.12-0.09-0.28-0.28Numero medio di azioni ordinarie in circolazione——169.79 M172.66 M200.19 M230.12 M913.38 MAzioni diluite in circolazione——169.79 M172.66 M200.19 M230.12 M913.38 MEBITDA-25.62 M-48.55 M-21.94 M-24.53 M33.54 M-36.56 M-36.56 MEBIT-26.45 M-49.21 M-22.52 M-24.73 M-21.48 M-36.62 M-36.62 MCosto del fatturato385 K1.43 M728 K671 K334 K——Altri costi del venduto———————Ammortamento e svalutazione (liquidità)823 K663 K582 K202 K55.02 M59 K59 K
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.